News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Unichem Laboratories has reported total income of Rs. 445.65 crores during the period ended December 31, 2023
Sun Pharma Advanced Research Company has reported total income of Rs. 20.25 crores during the period ended December 31, 2023
RPG Life Sciences Limited has reported total income of Rs. 155.62 crores during the period ended December 31, 2023
TTK Healthcare has reported total income of Rs. 199.75 crores during the period ended December 31, 2023
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
